Department of Preventive Medicine and Public Health, University of Kansas School of Medicine, Kansas City, KS, USA.
Tobacco Research and Treatment Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Addiction. 2017 Dec;112(12):2227-2236. doi: 10.1111/add.13913. Epub 2017 Aug 23.
To estimate the prevalence and predictors of failed biochemical verification of self-reported abstinence among participants enrolled in trials of hospital-initiated smoking cessation interventions.
Comparison of characteristics between participants who verified and those who failed to verify self-reported abstinence.
Multi-site randomized clinical trials conducted between 2010 and 2014 in hospitals throughout the United States.
Recently hospitalized smokers who reported tobacco abstinence 6 months post-randomization and provided a saliva sample for verification purposes (n = 822).
Outcomes were salivary cotinine-verified smoking abstinence at 10 and 15 ng/ml cut-points. Predictors and correlates included participant demographics and tobacco use; hospital diagnoses and treatment; and study characteristics collected via surveys and electronic medical records.
Usable samples were returned by 69.8% of the 1178 eligible trial participants who reported 7-day point prevalence abstinence. The proportion of participants verified as quit was 57.8% [95% confidence interval (CI) = 54.4, 61.2; 10 ng/ml cut-off] or 60.6% (95% CI = 57.2, 63.9; 15 ng/ml). Factors associated independently with verification at 10 ng/ml were education beyond high school education [odds ratio (OR) = 1.51; 95% CI = 1.07, 2.11], continuous abstinence since hospitalization (OR = 2.82; 95% CI = 2.02, 3.94), mailed versus in-person sample (OR = 3.20; 95% CI = 1.96, 5.21) and race. African American participants were less likely to verify abstinence than white participants (OR = 0.64; 95% CI = 0.44, 0.93). Findings were similar for verification at 15 ng/ml. Verification rates did not differ by treatment group.
In the United States, high rates (40%) of recently hospitalized smokers enrolled in smoking cessation trials fail biochemical verification of their self-reported abstinence.
评估参与医院启动戒烟干预试验的参与者中，自我报告的戒断经生物化学验证失败的发生率和预测因素。
比较经生物化学验证和未通过自我报告的戒断参与者的特征。
2010 年至 2014 年期间，在美国各地的医院进行的多地点随机临床试验。
最近住院的吸烟者，他们在随机分组后 6 个月报告了烟草戒断，并提供了唾液样本进行验证（n=822）。
结果为以 10 和 15ng/ml 切点的唾液可替宁验证的吸烟戒断率。预测因素和相关因素包括参与者的人口统计学和烟草使用情况；医院诊断和治疗；以及通过调查和电子病历收集的研究特征。
在报告 7 天点流行率戒断的 1178 名合格试验参与者中，有 69.8%的人提供了可用样本。被确认为戒烟者的参与者比例为 57.8%（95%置信区间 [CI]：54.4，61.2；10ng/ml 切点）或 60.6%（95% CI：57.2，63.9；15ng/ml）。与在 10ng/ml 时进行验证独立相关的因素包括高中以上教育（优势比 [OR]：1.51；95% CI：1.07，2.11）、自住院以来持续戒断（OR：2.82；95% CI：2.02，3.94）、邮件与当面样本（OR：3.20；95% CI：1.96，5.21）和种族。与白人参与者相比，非裔美国参与者更不可能验证戒断（OR：0.64；95% CI：0.44，0.93）。在 15ng/ml 时验证结果相似。验证率不因治疗组而异。
在美国，参加戒烟试验的最近住院吸烟者中，有很高的比例（40%）未能通过生物化学验证他们自我报告的戒断。
